Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray

• DOI: 10.1007/s00216-015-9257-2
• Publication Date: 2015-12-29T09:36:36Z
• Authors: Liu Shi; Thomas Gehin; Yann Chevolot; Eliane Souteyrand; Alain Mangé; Jérôme Solassol; Emmanuelle Lauren...
• Keywords: [SDV.BIO]Life Sciences [q-bio]/Biotechnology; [SDV.IMM] Life Sciences [q-bio]/Immunology; Protein Array Analysis; Protein microarray; [SDV.CAN]Life Sciences [q-bio]/Cancer; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; 03 medical and health sciences; Breast cancer; [SDV.CAN] Life Sciences [q-bio]/Cancer; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Prospective Studies; [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]; [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]; Heat-Shock Proteins; Autoantibodies; Neoplasm Staging; Immunoassay; 0303 health sciences; Heat shock proteins; [SDV.BIO] Life Sciences [q-bio]/Biotechnology; 3. Good health; Case-Control Studies; [SDV.IMM]Life Sciences [q-bio]/Immunology; Female

Heat shock proteins (HSPs) are over-expressed in a wide range of human cancers. It results in the stimulation of the immune system and consequently in elevated concentration of anti-HSP autoantibodies. Elevated anti-HSP autoantibodies were found in breast cancer patients, and they are associated with tumor metastasis. Therefore, screening these autoantibodies could be of diagnostic and prognostic values. Protein microarrays have already demonstrated their great potential as a diagnostic tool. However, protein diversity requires optimization of the microarray fabrication to achieve high sensitivity and specificity. In this study, seven HSPs were immobilized on six different surface chemistries. After evaluation and optimization with purified antibodies of the six surface chemistries, two surfaces were selected to detect anti-HSP autoantibodies in breast cancer sera. Multiplex detection of anti-HSP autoantibodies allowed discrimination of breast cancer patients (50) from healthy controls (26) with a sensitivity of 86% and a specificity of 100%.